The primary objective of the study is to determine the incidence, type, and pattern of serious adverse events, including but not limited to serious infections (including opportunistic infections), hepatic events, malignancies, and renal events, and of adverse events leading to treatment discontinuation, in patients with MS treated with DMF. Secondary study objectives are to (1) determine DMF prescription and utilization patterns in routine clinical practice in patients with MS; (2) assess the effectiveness of DMF on MS disease activity and disability progression; and (3) assess the effect of DMF on patient health-related quality of life, healthcare resource consumption, and work productivity.
A number of veterans suffer from multiple sclerosis (MS), a devastating and debilitating disease for which there is not cure or significant treatment. The only therapy available is immunomodulatory, but does not treat the neurodegeneration. The studies proposed in this application will develop therapeutic strategies and identify a drug that ameliorates inflammation as well as neurodegeneration in the disease. Thus, the effect of this drug will not only help veterans with MS, but will also benefit individuals with the disease in general.